Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
30 results
D1.297 - Clinical characteristics of red meat allergy in 19 cases in Jeju
D1.289 - The buzz that nearly broke a heart: A case of Kounis Syndrome following a Hymenoptera sting
D1.290 - Identification of a Cheese-Derived κ-Casein Fragment as the Trigger of Anaphylaxis in a Patient with Suspected Pasta Allergy
D1.291 - Real-world data of nasal adrenaline spray in anaphylaxis: Review of clinical evidence
D1.292 - Anaphylaxis After Roasted Sunflower Seed Consumption in an Adult: A Case Report
D1.293 - Hidden allergens revealed by prick-to-prick testing: anaphylaxis triggered by black pepper and cumin
D1.295 - Patient Perceived Lifestyle Burden with a Nasal Adrenaline Spray vs an Adrenaline Auto- Injector
D1.296 - Nasal Adrenaline Spray vs Adrenaline Auto-Injectors: When Will People Act?
D1.298 - Does Previous Anaphylaxis Determine Differences between Patients Undergoing Oral Food Challenges to Cow’s Milk and Hen’s Egg?
D1.299 - Lychee-Induced Anaphylaxis: Data from the French Allergy-Vigilance Network since 2002
D1.301 - Non-specific lipid transfer protein allergy: the culprit in disguise
D1.302 - Allergic Reactions Following Measles-Mumps-Rubella Vaccination in Children with Food Allergy: A Single Center Experience
D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial
D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial
D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial
D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study
D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study
D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis
D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial
D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download